Assessing the effects of deprenyl on longevity and antioxidant defenses in different animal models

Annals of the New York Academy of Sciences

Volumn 854, Issue , 1998, Pages 291-306

  Kitani, Kenichi ^a   Kanai, Setsuko ^b   Ivy, Gwen O ^c   Carrillo, Maria Cristina ^d  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ANTIPARKINSON AGENT; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; MANGANESE SUPEROXIDE DISMUTASE; SCAVENGER; SELEGILINE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN REGION; CANCER INHIBITION; CONFERENCE PAPER; CORPUS STRIATUM; DOG; DOPAMINERGIC SYSTEM; ENZYME ACTIVITY; FEMALE; HAMSTER; HIPPOCAMPUS; IMMUNE SYSTEM; LONGEVITY; MALE; MOUSE; NONHUMAN; RAT; SPECIES DIFFERENCE; SUBSTANTIA NIGRA;

ANIMALIA; CANIS FAMILIARIS; CRICETINAE; FELIS CATUS; RODENTIA;

EID: 0032424803     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb09910.x     Document Type: Conference Paper

References (36)

1. HARMAN, D. 1994. Free-radical theory of aging. Increasing the functional life span. In Pharmacology of Aging Processes. Methods of Assessment and Potential Interventions. I. Zs.-Nagy, D. Harman & K. Kitani, Eds.: 717: 1-15. Annals of the New York Academy of Sciences. New York.
2. + in vivo. Eur. J. Pharmacol. 243: 241-247.
3. KNOLL, J. 1988. The striatal dopamine dependency of life span in male rats: Longevity study with (-)deprenyl. Mech. Ageing Dev. 46: 237-262.
4. CARRILLO, M.C., S. KANAI, M. NOKUBO & K. KITANI. 1991. (-)Deprenyl induces activities of both Superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci. 48: 517-521.
5. CARRILLO, M.C., K. KITANI, S. KANAI, Y. SATO & G.O. IVY. 1992. The ability of (-)deprenyl to increase Superoxide dismutase activities in the rat is tissue and brain region selective. Life Sci. 50: 1985-1992.
6. CARRILLO, M.C., S. KANAI, M. NOKUBO, G.O. IVY, Y. SATO & K. KITANI. 1992. (-)Deprcnyl increases activities of Superoxide dismutase and catalase in striatum but not in hippocampus: The sex and age-related differences in the optimal dose in the rat. Exp. Neurol. 116: 286-294.
7. CARRILLO, M.C., S. KANAI, Y. SATO, G.O. IVY & K. KITANI. 1992. Sequential changes in activities of Superoxide dismutase and catalase in brain regions and liver during (-)deprenyl infusion in male rats. Biochem. Pharmacol. 44: 2185-2189.
8. CARRILLO, M.C., S. KANAI, Y. SATO, M. NOKUYBO, G.O. IVY & K. KITANI. 1993. The optimal dosage of (-)deprenyl for increasing Superoxide dismutase activities in several brain regions decreases with age in male Fischer 344 rats. Life Sci. 52: 1925-1934.
9. CARRILLO, M.C., K. KITANI, S. KANAI, Y. SATO, K. MIYASAKA & G.O. IVY. 1994. The effect of a long term (6 months) treatment with (-)deprenyl on antioxidant enzyme activities in selective brain regions in old female Fischer 344 rats. Biochem. Pharmacol. 47: 1333-1338.
10. MILGRAM, N.W., R.J. RACINE, P. NELLIS, A. MENDONCA & G.O. IVY. 1990. Maintenance of L-deprenyl prolongs life in aged male rats. Life Sci. 47: 415-420.
11. KITANI, K., S. KANAI, Y. SATO, M. OHTA, G.O. IVY & M.C. CARRILLO. 1993. Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats: Further evidence. Life Sci. 52: 281-288.
12. STOLL, S., U. HAFNER, B. KRÄNZLIN & W.E. MüLLER. 1997. Chronic treatment of Syrian hamsters with low-dose selegiline increases life span in females but not males. Neurobiol. Aging 18: 205-211.
13. RUEHL, W.W., T.L. ENTRIKEN, B.A. MUGGENBURG, D.S. BRUYETTE, W.G. GRIFFITH & F.F. HAHN. 1997. Treatment with L-deprenyl prolongs life in elderly dogs. Life Sci. 61: 1037-1044.
14. KITANI, K., S. KANAI, M.C. CARRILLO & G.O. IVY. 1994. (-)Deprenyl increases the life span as well as activities of Superoxide dismutase and catalase but not of glutathione peroxidase in selective brain regions in Fischer rats. In Pharmacology of Aging Processes. Methods of Assessment and Potential Interventions. I. Zs.-Nagy, D. Harman & K. Kitani, Eds.: 717: 60-71. Annals of the New York Academy of Sciences. New York.
15. KITANI, K., K. MIYASAKA, S. KANAI, M.C. CARRILLO & G.O. IVY. 1996. Upregulation of antioxidant enzyme activities by deprenyl: Implications for life span extension. In Pharmacological Intervention in Aging and Age-Associated Disorders. K. Kitani, A. Aoba & S. Goto, Eds.: 726: 391-409. Annals of the New York Academy of Sciences. New York.
16. INGRAM, D.K., H.L. WIENER, M.E. CHACHICH, J.M. LONG, J. HENGEMIHLE & M. GUPTA. 1993. Chronic treatment of aged mice with L-deprenyl produces marked MAO-B inhibition but no beneficial effects on survival, motor performance, or nigral lipofuscin accumulation. Neurobiol. Aging 14: 431-440.
17. PlANTANELLI, L., A. ZAIA, G. ROSSOLINI, C. VlTICECHI, R. TESTA, A. BASSO & A. ANTOGNINI. 1994. Influence of L-deprenyl treatment on mouse survival kinetics. In Pharmacology of Aging Processes. Methods of Assessment and Potential Interventions. I. Zs.-Nagy, D. Harman & K. Kitani, Eds.: 717: 72-78. Annals of the New York Academy of Sciences. New York.
18. ARCHER, J.R. & D.E. HARRISON. 1996. L-Deprenyl treatment in aged mice slightly increases life spans, and greatly reduces fecundity by aged males. J. Gerontol. Biol. Sci. 31A: B448-B453.
19. KNOLL, J. 1990. Advances in Neurology. Vol. 53. Parkinson's Disease: Anatomy, Pathology and Therapy. 425-429. Raven Press. New York.
20. CARRILLO, M.C., K. KITANI, S. KANAI, Y. SATO, K. MIYASAKA & G.O. IVY. 1994. (-)Deprenyl increases activities of Superoxide dismutase and catalase in certain brain regions in old male mice. Life Sci. 54: 975-981.
21. CARRILLO, M.C., N.W. MILGRAM, P. Wu, G.O. IVY & K. KITANI. 1994. (-)Deprenyl increases activities of Superoxide dismutase (SOD) in striatum of dog brain. Life Sci. 54: 1483-1489.
22. CARRILLO, M.C., K. KITANI, S. KANAI, Y. SATO, G.O. IVY & K. MIYASAKA. 1996. Long term treatment with (-)deprenyl reduces the optimal dose as well as the effective dose range for increasing antioxidant enzyme activities in old mouse brain. Life Sci. 59: 1047-1057.
23. KNOLL, J., Z. ECSERI, K. KELEMEN, J. NIEVEL & B. KNOLL. 1965. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch. Int. Phamacodyn. Ther. 155: 154-164.
24. KNOLLEMA, S., W. AUKEMA, H. HOM, J. KORF & G.J.T. HORST. 1995. L-Deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke 26: 1883-1887.
25. RUEHL, W.W., D. BICE, B. MUGGENBURG, D.D. BRUYETTE & D.R. STEVENS. 1994. L-Deprenyl and canine longevity: Evidence for an immune mechanism, and implications for human aging. 2nd Conference on Anti-Aging Medicine, Las Vegas. Abstract p. 25-26.
26. KITANI, K., M.C. CARRILLO, S. KANAI, Y. SATO & G.O. IVY. 1993. Chronic treatment of (-)deprenyl abolishes the dose effect on the Superoxide dismutase (SOD) and catalase (CAT) in striatum in the rat The XVth Congress of the International Association of Gerontology. Abstract p. 164.
27. BIRKMAYER, W., J. KNOLL, M.B.H. RIEDER, V.H. YOUDIM & J. MARTON. 1985. Improvement of life expectancy due to L-deprenyl addition to Madopar treatment in Parkinson's disease: A long-term study. J. Neural. Transm. 64: 113-127.
28. LEES, A J. 1995. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br. Med. J. 311: 1602-1607.
29. THE PARKINSON STUDY GROUP. 1989. Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321: 1364-1371.
30. TETRUD, J.W. & J.W. LANGSTON. 1989. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245: 519-522.
31. CALZOTTI, S., A. NEGRATTI & A. CASSIO. 1995. L-Deprenyl as an adjunct to low-dose bromocriptine in early Parkinson's disease: A short-term, double blind, and prospective study. Clin. Neuropharmacol. 18: 250-257.
32. COHEN, G., P. PASIK, B. COHEN, A. LEIST, C.Y. MYTILINEOU & M.D. YAHR. 1984. Pargyline and (-)deprenyl prevent the neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. 106: 209-210.
33. VIZUETC, M.L., V. STEFFEN, A. AYALA, J. CANO & A. MACHADO. 1993. Protective effect of deprenyl against l-methyl-4-phenylpyridinium neurotoxicity in rat striatum. Neurosci. Lett. 152(1-2): 113-116.
34. SALO, P.T. & W.G. TATTON. 1992. Deprenyl reduces the death of motoneurons caused by axotomy. J. Neurosci. Res. 31: 394-400.
35. MAZZINI, L., D. TESTA, C. BALZARINI & G. MORA. 1994. An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis. J. Neurol. 241: 223-227.
36. SANO, M., C. ERNERSTO, R.G. THOMAS, M.R. KLAUBER, K. SCHAFFER, M. GRUNDMAN, H.P. WOODBURY, J. GROUDON, C.W. COTMAN, E. PFEIFFER, L.S. SCHNEIDER & L.J. THAL. 1997. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N. Engl. J. Med. 336: 1216-1222.